OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas
December 22, 2022Business Services
Nantes, France – December 22,
Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery
December 21, 2022Medical Communications
LONDON, UK, 21st December 2022 — RQ Bio announces that the first of its discovered monoclonal antibodies to prevent COVID-19 …
Kite set to acquire Tmunity Therapeutics
December 21, 2022Medical Communications
Santa Monica, US-based Kite is set to acquire Philadelphia, US-based Tmunity Therapeutics: a clinical stage, private biotech company. The financial …
Two biotech CEOs charged with defrauding investors over investigational HIV drug
December 21, 2022Medical Communications
Two US biotech CEOs have been highlighted for their roles in a conspiracy to defraud investors in CytoDyn, a company …
Gambia panel recommends Maiden Pharmaceuticals be held culpable for cough syrup deaths
December 21, 2022Medical Communications
A parliamentary committee in The Gambia has recommended prosecution of the Indian pharma manufacturer Maiden Pharmaceuticals, as they have sold …
Tamiflu manufacturers report shortages during high point of flu season
December 21, 2022Medical Communications
The CDC has reported at least 23,000 hospitalisations due to influenza while this year’s flu season is at a high …
Sosei Heptares’ Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
December 21, 2022Business Services
Tokyo, Japan and Cambridge, UK, 21 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
December 21, 2022Business Services
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it …
NICE EXTENDS USE OF ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) TO EARLIER IN THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
December 20, 2022Business Services
Uxbridge and London, UK – (20 December 2022) – Daiichi Sankyo UK Limited and AstraZeneca UK Limited today welcome the …
Idorsia submits new drug application to FDA for aprocitentan to treat difficult-to-control hypertension
December 20, 2022Research and Development
Idorsia has announced that it has submitted a new drug application (NDA) to the FDA in hopes of gaining approval …
AlzeCure has abstract accepted on possible disease-modifying effects of ACD856 against Alzheimer’s
December 20, 2022Research and Development
AlzeCure, a pharma company who focuses on its portfolio of small molecule candidate drugs for central nervous system (CNS) diseases, …
ServBlock secures EU funding for pharma manufacturing data space
December 20, 2022Medical Communications
ServBlock, an Irish start-up, and Irish Manufacturing Research (IMR), have been given EU funding to build a data exchange system …
Abbott’s Eterna spinal cord stimulation system given FDA approval
December 20, 2022Medical Communications
US-based Abbott Laboratories has announced that their Eterna spinal cord stimulation (SCS) system has been given approval by the FDA. …
Unison boss states Government has “adamantly refused” to engage in a “proper discussion” on pay ahead of Wednesday’s ambulance strikes
December 19, 2022Medical Communications
Unison general secretary Christina McAnea has said that Wednesday’s ambulance strikes will go ahead without a “very firm commitment” on …
FDA approves first gene therapy to treat patients with high-risk, non-muscle-invasive bladder cancer
December 19, 2022Medical Communications
The FDA has approved Adstiladrin (scientific name nadofaragene firadenovec-vncg) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive …
New study shares effectiveness of asthma drug compared to standard of care
December 19, 2022Research and Development
The University of Plymouth has co-authored a new study, published in The Lancet, which shows how an asthma drug, commercially …
Targeted imaging agent for lung cancer surgery approved by FDA
December 19, 2022Research and Development
The FDA has approved Cytalux (pafolacianine) to be used in lung cancer surgery: the targeted imaging agent binds to cancerous …
Psoriasis community comes together and calls for collective action to help improve the lives of people with psoriasis
December 19, 2022Business Services
Slough, UK, 15 December 2022 – UCB, a global biopharmaceutical company, has announced results from the Epicensus programme, published in …
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
December 19, 2022Business Services
Tokyo, Japan and Cambridge, UK, 16 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) announces it has entered …
Alchemab Therapeutics and Medicines Discovery Catapult awarded £1.7 million grant from Innovate UK to accelerate development of disease-modifying therapy for Huntington’s Disease
December 19, 2022Business Services
Cambridge, UK. December 16 2022 – Alchemab Therapeutics, a biotechnology company unlocking new therapies from within the immune system, today …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
